SKLB06329

SKLB06329 is a potent selective Type I PRMTs inhibitor. SKLB06329 shows good selectivity for PRMT6 (IC50 = 3.86 nM) over Type II/III PRMTs (PRMT5/7) and shows no significant inhibition against various lysine methyltransferases (PKMTs). SKLB06329 significantly inhibits the proliferation of triple-negative breast cancer (TNBC) cells, induces apoptosis, and suppresses the expression of asymmetric dimethylarginine (ADMA) within cells. SKLB06329 can be used for triple-negative breast cancer research.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Fòrmula: C20H25N5O2S
  • Peso molecular:399.51
  • Almacenamiento:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Actividad biológica
  • Chemical Information
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
100 mg

Obtener un presupuesto En stock

Please select quantity
Amount: USD 0.00